Replies to post #3597 on RespireRx Pharmaceuticals Inc (fka RSPI)

[striaterminalis]

what would that indicate, in your opinion?

[haysaw]

It's probable nothing. Maybe something with the AMEX, or the market maker had an emergency and had to leave early. The same thing must have happened to TTP. Both are showing 0 on the bid and ask.

[dominate]

Parkinson's Therapeutics Reviewed by NeuroInvestment
Monday February 5, 9:00 am ET


CARDIFF, CA--(MARKET WIRE)--Feb 5, 2007 -- NI Research has released the February issue of NeuroInvestment, which reviews the status and prospects of Parkinson's therapeutics. Parkinson's is estimated to affect 1.5 million Americans, and with the aging population, its prevalence is likely to double in the next few decades. While the initial treatment of Parkinson's with levodopa is a relative success story for neurology, the fact is that current treatments for Parkinson's are either only temporary in nature, with symptoms becoming even more virulent after five years, or are only partially effective.

This review covers both potential improvements in the compensatory treatments currently available, and next-generation neuroprotective and neuroregenerative therapies in development. There are improved delivery options from UCB Pharma, Amarin, and earlier on, such companies as NuPathe. Adjunctive drug therapies include compounds from Serono/Newron, Neurogen, and Acadia (NasdaqGM:ACAD - News). Possible neuroprotectants are in development by Biogen-Idec, Neurocrine Biosciences (NasdaqGS:NBIX - News), Avicena, Allon Therapeutics, Lilly, NeuroNova, and Amarin. Cutting-edge cell and gene therapy approaches are being developed by such companies as Schering/Titan, Ceregene, Neurologix, Genzyme, and Oxford Biomedica.

The February NeuroInvestment also takes a closer look at such topics as Acadia Pharmaceuticals' ACP-104, D-Pharm, Vanda, and Cephalon, with a full review of Faust Pharmaceuticals. The latest information regarding the improved prospects for Cortex Pharmaceuticals (AMEX:COR - News) and its development of CX717 for ADHD is included.

This follows in the wake of the January NI overview of the CNS sector, which assessed the high and lowpoints of 2006, prospects for 2007, including commentary on Vanda Pharmaceuticals and a full review of Torrey Pines Therapeutics.